Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00048477 |
Recruitment Status :
Completed
First Posted : November 1, 2002
Last Update Posted : March 4, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Nitric oxide gas is important in regulating blood vessel dilation, and consequently, blood flow. This gas is continuously produced by endothelial cells, which line the blood vessels. This study will examine whether nitrite, a molecule that normally circulates in the blood stream, can also dilate blood vessels. The results of this study may be valuable in developing treatments for people with conditions associated with impaired endothelial production of nitric oxide, including high blood pressure, high blood cholesterol, diabetes, estrogen deficiency, and others.
Healthy, non-smoking normal volunteers 21 years of age or older may be eligible for this study. People who lack the enzyme G6PD or cytochrome B5 in their red blood cells may not participate. Absence of these enzymes can lead to episodes of sudden shortness of breath and cyanosis (blueness of the skin due to lack of sufficient oxygen). Participants will undergo the procedures described in study Parts A and B, as follows:
- Part A - After numbing the skin, small tubes are placed in the artery and vein at the inside of the elbow of the dominant arm (right- or left-handed) and a small tube is placed in a vein of the other arm. The tubes are used for infusing saline (salt water) and for drawing blood samples. A pressure cuff is placed around the upper part of the dominant arm, and a rubber band device called a strain gauge is also placed around the arm to measure blood flow. When the cuff is inflated, blood flows into the arm, stretching the strain gauge at a rate proportional to the flow. Grip-strength of the dominant arm is measured with a dynamometer to determine maximum grip-strength. Then, several measurements of blood flow, nitrite, hemoglobin, and handgrip are made before and after administration of L-NMMA, a drug that blocks endothelial production of nitric oxide.
- Part B - Part A testing is repeated, except that sodium nitrite dissolved in a saline solution is infused into the artery of the forearm for a few minutes before and during the hand-grip exercises. In addition, blood samples are drawn before and after each handgrip exercise to measure methemoglobin, a substance that, at excessive levels, can cause adverse side effects.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Nitric Oxide Endothelium-Derived Relaxing Factor Healthy | Drug: L-NMMA and Sodium Nitrite | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 42 participants |
Primary Purpose: | Treatment |
Official Title: | Determination of Nitrite as a Source of Bioactive Nitric Oxide in Human Subjects |
Study Start Date : | October 2002 |
Study Completion Date : | November 2003 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA
All volunteer subjects must be at least 21 years of age in good health and have provided informed, written consent for participation in this study.
EXCLUSION CRITERIA
Subjects with a history or evidence of present or past hypertension (blood pressure greater than 145/95 mmHg), hypercholesterolemia (LDL cholesterol greater than 130 mg/dL), diabetes mellitus (fasting blood glucose greater than 130 mg/dL), smoking within two years, cardiovascular disease, peripheral vascular disease, coagulopathy, or any other disease predisposing to vasculitis or Raynaud's phenomenon.
All subjects will be tested for red blood cell G6PD deficiency; levels below the lower limits of normal will result in exclusion from participation in the study.
Subjects with a known cytochrome B5 deficiency will not participate in this study.
Subjects with a history of reaction to a medication or other substance characterized by dyspnea and cyanosis will not participate in this study.
Subjects with a baseline methemoglobin level greater than 1% will not receive nitrite infusions.
Lactating and pregnant females.
No volunteer subject will be allowed to take any medication (oral contraceptive agents are allowed), vitamin supplements, herbal preparations, nutriceuticals or other 'alternative therapies' for at least one month prior to study and will not be allowed to take aspirin for one week prior to study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00048477
United States, Maryland | |
National Heart, Lung and Blood Institute (NHLBI) | |
Bethesda, Maryland, United States, 20892 |
ClinicalTrials.gov Identifier: | NCT00048477 |
Other Study ID Numbers: |
030020 03-H-0020 |
First Posted: | November 1, 2002 Key Record Dates |
Last Update Posted: | March 4, 2008 |
Last Verified: | November 2003 |
Endothelium Vasodilation Exercise Hemoglobin |
Blood Flow Healthy Volunteer HV |
omega-N-Methylarginine Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |